SUMMIT SECURES $1.5M AGREEMENT WITH US DMD ORGANISATIONS • Proceeds to fully fund new Phase I clinical trial of Summit's potential first-in-class DMD drug SMT C1100 • SMT C1100 has the potential to treat all DMD patients Oxford, UK, 19 December 2011, Summit (AIM: SUMM), a UK drug discovery company, announces that it has entered into agreements collectively worth $1.5 million with several US-based…